The authors performed a 2 institutional retrospective study to analyze treatment and survival of patients with angiosarcoma of bone. Complete surgical resection is essential for outcome.
READ FULL ARTICLE
From Mdlinx
According to a new study published in the American Journal of Clinical Oncology, complete surgical resection of primary angiosarcoma of bone is associated with better outcomes.
For the retrospective study, researchers sought to analyze treatments with activity and survival of patients with primary angiosarcoma of bone. They identified 60 patients with a median age of 54 year who were treated between 1980 and 2009.
Lesions were commonly found in the femur and pelvis, and 40% of patients had metastatic disease at the time of diagnosis. Nearly 72% of patients underwent surgery and about 70% of those patients achieved surgical complete remission. About 28% of patients received radiotherapy, 13 of those with localized disease received chemotherapy, and 15 of those with metastatic disease received chemotherapy.
Results showed that the 5-year overall survival was 20%. Specifically, the 5-year overall survival was 33% for those with localized disease and 0% for those with metastatic disease. Patients without metastatic disease had improved overall after achieving surgical complete remission and adjuvant chemotherapy with cisplatin, doxorubicin, and ifosfamide.
Of the 15 patients who received chemotherapy for metastatic disease, two RECIST partial responses were observed out of 13 evaluable patients, 1 of whom received paclitaxel and the other who received doxorubicin. Two patients had stable disease.
The authors performed a 2 institutional retrospective study to analyze treatment and survival of patients with angiosarcoma of bone. Complete surgical resection is essential for outcome.
READ FULL ARTICLE
From Mdlinx
You’ve read {{metering-count}} of {{metering-total}} articles this month.
We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.
{{login-button}} {{register-button}}
Want to view more content from Cancer Therapy Advisor?
Register now at no charge to access unlimited clinical news, full-length features, case studies, conference coverage, and more.
{{login-button}} {{register-button}}
Please login or register first to view this content.